Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsArizona Complete Health Relistor Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentArizona Complete HealthPolicy AZ.CP.PMN.169

    Clinical Policy: Methylnaltrexone Bromide (Relistor)

    Customize your policy alerts

    Sign up for Arizona Complete Health Policy AZ.CP.PMN.169 alerts

    Get alerted when Policy AZ.CP.PMN.169 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Arizona Medicaid coverage and prior authorization for Relistor tablets and injection to treat opioid-induced constipation in adults, including initial and continued-therapy requirements, dosing limits, exclusions, and documentation.

    Policy Summary
    PayerArizona Complete Health
    PolicyClinical Policy: Methylnaltrexone Bromide (Relistor)
    Policy CodePolicy AZ.CP.PMN.169
    Change TypeAdministrative/reference maintenance only
    Effective DateSep 19, 2019
    Last ReviewOct 1, 2020
    Next Review DateN/A
    Key ActionSubmit clinical documentation showing that the member meets all applicable Relistor approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+ yearsMinimum age for initial OIC approval
    6 monthsInitial approval duration
    12 monthsContinued OIC therapy approval duration
    450 mg/dayMaximum Relistor tablet dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Mechanical GI obstruction
    Contraindication to Relistor

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of opioid-induced constipation (OIC).
    • Member is age 18 years or older.>= 18 years
      • ONE agent from each class

        • Stimulant laxative (e.g., bisacodyl, senna).
        • Osmotic laxative (e.g., lactulose, polyethylene glycol).
        • Stool softener (e.g., docusate).
    • Member has used one of the aforementioned agents within the past 30 days, unless contraindicated.
    • For members with chronic non-cancer pain ONLY

      • Member has been taking opioid(s) for at least 4 weeks.>= 4 weeks
      • Failure of Amitiza, unless contraindicated or clinically significant adverse effects are experienced.

        Prior authorization may be required for Amitiza.

    • Requested dose does not exceed the applicable limit: tablets 450 mg per day (3 tablets per day); injection FDA-approved weight-based dosing (see Section V).

    Continuation Therapy

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Currently receiving medication via the Centene benefit or member has previously met initial approval criteria.
    • Member continues to receive opioid therapy.
    • Member is responding positively to therapy.
    • If the request is for a dose increase, the new dose does not exceed the applicable limit: tablets 450 mg per day (3 tablets per day); injection FDA-approved weight-based dosing (see Section V).

    Other Diagnoses or Indications

    Coverage is available when at least ONE of the following pathways is met:

    ONE of the following

    • Member is currently receiving the medication via the Centene benefit and documentation supports a positive response to therapy.

      Approval duration: 6 months.

    • If the diagnosis is not specifically listed under Section III (Diagnoses/Indications for which coverage is NOT authorized), refer to the off-label use policy for the relevant line of business: AZ.CP.PMN.53 for Arizona Medicaid.

      Approval duration: duration of request or 12 months, whichever is less.

    Coverage is not authorized for non-FDA-approved indications that are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the applicable off-label use policy, AZ.CP.PMN.53 for Arizona Medicaid.

    Methylnaltrexone bromide is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction and in patients at increased risk of recurrent obstruction. No boxed warnings are reported.

    Clinical and Dosing Parameters

    Minimum Age
    Minimum ageAt least 18 years
    Applies toInitial approval for opioid-induced constipation
    RequirementMember must be 18 years of age or older
    Opioid Therapy Duration
    Minimum opioid durationAt least 4 weeks
    Applies toMembers with chronic non-cancer pain
    RequirementMember must have been taking opioid(s) for at least 4 weeks

    Prior Authorization and Documentation

    Prior Authorization

    Relistor Prior Authorization Documentation

    Submit documentation demonstrating that the member meets all applicable Relistor approval criteria. Documentation may include office chart notes, laboratory results, or other supporting clinical information.

    Step Therapy

    Amitiza Prerequisite

    For members with chronic non-cancer pain, document failure of Amitiza (lubiprostone) before Relistor is approved, unless Amitiza is contraindicated or caused clinically significant adverse effects. Prior authorization may be required for Amitiza.

    Step Therapy

    Required Laxative Sequencing

    Document failure of one agent from each required laxative class while the member is receiving opioid therapy, unless all are contraindicated or clinically significant adverse effects occurred. The member must also have used one of these agents within the past 30 days, unless contraindicated.

    Therapy Overview

    Methylnaltrexone bromide (Relistor) is an opioid antagonist used to treat opioid-induced constipation (OIC). This policy addresses coverage for adults with chronic non-cancer pain and adults with advanced illness or active cancer-related pain who require opioid dose escalation for palliative care. Relistor is available as oral tablets and subcutaneous injection, with dosing determined by the indication and, for some injection regimens, the patient’s weight.

    Policy Terms

    FDA
    AbbreviationFDA
    Full termFood and Drug Administration
    Source locationAppendix A: Abbreviation/Acronym Key
    OIC
    AbbreviationOIC
    DefinitionOpioid-induced constipation
    Source locationAppendix A: Abbreviation/Acronym Key

    Initial OIC Approval

    Initial OIC Approval

    Initial Relistor approval for opioid-induced constipation requires all applicable criteria.

    Initial Relistor approval

    • The member has a diagnosis of opioid-induced constipation and is at least 18 years old.Age ≥18 years
    • Required laxative therapy

      • The member has failed one agent from each of the following classes while on opioid therapy, unless all are contraindicated or clinically significant adverse effects are experienced: stimulant laxative, osmotic laxative, and stool softener.One stimulant laxative, one osmotic laxative, and one stool softener

        Examples include bisacodyl or senna; lactulose or polyethylene glycol; and docusate.

    Continued OIC Therapy

    Continued OIC Therapy

    Continued Relistor therapy for opioid-induced constipation requires all listed criteria.

    Continued OIC therapy

    • The member is currently receiving the medication through the Centene benefit or previously met the initial approval criteria.
    • The member continues to receive opioid therapy.
    • The member is responding positively to therapy.
    • If a dose increase is requested, the new dose does not exceed the applicable policy limit.Tablets: ≤450 mg/day (3 tablets/day); injection: FDA-approved weight-based dosing

    Required Preceding Therapies

    StepRequired therapyRequirement details
    1Stimulant laxative, osmotic laxative, and stool softenerWhile on opioid therapy, the member must fail one agent from each class unless all are contraindicated or clinically significant adverse effects occur. Examples include bisacodyl or senna, lactulose or polyethylene glycol, and docusate. One of these agents must have been used within the past 30 days unless contraindicated.
    StepRequired therapyRequirement details
    2Amitiza (lubiprostone)For chronic non-cancer pain indications, the member must fail Amitiza after or alongside the required laxative-class therapy, unless Amitiza is contraindicated or causes clinically significant adverse effects. Amitiza may require prior authorization.

    Relistor Dose and Frequency Limits

    Relistor Tablets
    ProductRelistor tablets
    Maximum quantity limit450 mg per day
    Daily tablet limit3 tablets per day
    Relistor Injection — Chronic Non-Cancer Pain
    ProductRelistor injection for chronic non-cancer pain
    Maximum quantity limit12 mg per day
    RouteSubcutaneous
    Policy Summary
    PayerArizona Complete Health
    PolicyClinical Policy: Methylnaltrexone Bromide (Relistor)
    Policy CodePolicy AZ.CP.PMN.169
    Change TypeAdministrative/reference maintenance only
    Effective DateSep 19, 2019
    Last ReviewOct 1, 2020
    Next Review DateN/A
    Key ActionSubmit clinical documentation showing that the member meets all applicable Relistor approval criteria.
    SourceLink
    On This Page
    Coverage CriteriaClinical and Dosing ParametersPrior Authorization and DocumentationTherapy OverviewPolicy TermsInitial OIC ApprovalContinued OIC TherapyRequired Preceding TherapiesRelistor Dose and Frequency Limits
    Maximum Tablet Dose
    Maximum daily dose450 mg per day
    Maximum tablet quantity3 tablets per day
    Dosage formRelistor tablets for chronic non-cancer pain
    Advanced Illness Injection Frequency
    Maximum frequencyNo more frequently than one dose per 24-hour period
    IndicationOpioid-induced constipation in adults with advanced illness
    AdministrationSubcutaneous injection, as needed
    Chronic Non-Cancer Pain Injection Maximum
    Maximum daily dose12 mg per day
    RouteSubcutaneous
    IndicationOpioid-induced constipation in adults with chronic non-cancer pain
    • Stimulant laxative, such as bisacodyl or senna.
    • Osmotic laxative, such as lactulose or polyethylene glycol.
    • Stool softener, such as docusate.
    Documentation Required

    Supporting Clinical Information

    Include chart notes, laboratory results, or other clinical information supporting the diagnosis, treatment history, contraindications, adverse effects, opioid use, and all other applicable approval criteria.

    Documentation Required

    Initial Therapy Documentation

    For initial therapy, document opioid-induced constipation, member age of at least 18 years, current opioid use, and the required prior therapy. For chronic non-cancer pain, also document opioid therapy for at least 4 weeks and Amitiza failure or a contraindication/clinically significant adverse effect.

    • Document that the requested dose does not exceed 450 mg per day (three tablets per day) for tablets.
    • For injection requests, apply FDA-approved weight-based dosing.
    Documentation Required

    Continuation Documentation

    For continuation therapy, document that the member continues opioid therapy and is responding positively to Relistor. The request must be through the Centene benefit or the member must have previously met initial approval criteria.

    • For a dose increase, document that the new tablet dose does not exceed 450 mg per day (three tablets per day).
    • For injection dose increases, document FDA-approved weight-based dosing.
    Denial Risk

    Initial Criteria Not Met

    Initial approval may be denied when the member does not have opioid-induced constipation, is younger than 18 years, has not met the required laxative and Amitiza prerequisites, or lacks documentation of applicable opioid use, recent prior therapy, contraindication/adverse effects, or dose limits.

    Denial Risk

    Continuation Criteria Not Met

    Continuation approval may be denied when the member is not continuing opioid therapy, is not responding positively to Relistor, has not met the initial or continuation requirements, or requests a dose above the applicable tablet or injection limit.

    Denial Risk

    Unauthorized Indication

    Non-FDA-approved indications not addressed by this policy are not authorized unless sufficient documentation of efficacy and safety is submitted in accordance with the applicable off-label use policy. For Arizona Medicaid, refer to AZ.CP.PMN.53 when applicable.

    Denial Risk

    Mechanical Gastrointestinal Obstruction

    Relistor is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction who are at increased risk of recurrent obstruction. Do not proceed without addressing this contraindication.

    The member has used one of the required laxative agents within the past 30 days, unless contraindicated.Use within the past 30 days
  1. Additional chronic non-cancer pain criteria, when applicable

    • The member has been taking opioid therapy for at least 4 weeks and has failed Amitiza (lubiprostone), unless contraindicated or clinically significant adverse effects are experienced.Opioid therapy ≥4 weeks

      Prior authorization may be required for Amitiza.

  2. The requested dose does not exceed the applicable policy limit.Tablets: ≤450 mg/day (3 tablets/day); injection: FDA-approved weight-based dosing
  3. Relistor Injection — Advanced Illness
    ProductRelistor injection for advanced illness
    Maximum frequencyOne dose no more frequently than every 24 hours
    UseAs needed; subcutaneous, weight-based dosing